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A B S T R A C T
Trends toward pharmaceuticalization in Western countries have led to increased research and theorizing about
the roles macro-level institutions, structures, and collective actors play in contributing to patients’ reliance on
prescription drugs. Relatively less work has focused on the degree to which patients resist pharmaceuticalization
pressures, and even less research has explored the factors contributing to patients’ resistance to pharmaceuti-
calization. Drawing on focus groups with patients who had been recently prescribed a prescription drug, this
paper investigates how marginalization in the mainstream US society, as measured by acculturation and race,
contributes to differences in patients’ subjective experiences and responses to prescription drugs. We find that
racial minorities report a greater skepticism of prescription drugs compared to whites and express that they turn
to prescription drugs as a last resort. While highly acculturated participants rarely discuss alternatives to pre-
scription drugs, less acculturated racial minorities indicate a preference for complementary and alternative
remedies. We draw on the literatures on the pharmaceuticalization of society and the social nature of medicine
to examine the role marginalization plays in patients’ views of prescription drugs. Public health research con-
ceives of racial minorities’ lower rates of prescription drug usage compared to whites as primarily a problem of
lack of access. Our results suggest another piece to the puzzle: minorities resist pharmaceuticalization pressures
to express their cultural and racial identities.
1. Introduction
In recent years, there has been an upsurge in the use of prescription
drugs among Westerners. This rise in prescription medication use has
been particularly acute in the United States. “The World Medicines
Situation” report (Creese, Gasman, & Mariko, 2004) showed that in
1999, the major consumption of medicines by value (about 90%) took
place in high-income countries. Interestingly, the report also noted that
the market share for the US increased from 18.4% in 1976 to 52% in
2000. A US study examining trends in the prevalence of prescription
drug use in nationally representative data from the National Health and
Nutrition Examination Survey (NHANES) found that general prescrip-
tion drug use had risen from 51% in 1999–2000 to 59% in 2011–2012
(Kantor, Rehm, Haas, Chan, & Giovannucci, 2015).
Though the prevalence of prescription drugs in the US is quite high,
there are substantial differences in use by race. Briesacher, Limcangco,
and Gaskin (2003) found that Black and Hispanic Medicare bene-
ficiaries received less chronic illness medications compared to white
beneficiaries. Another study (Gaskin, Briesacher, Limcangco, &
Brigantti, 2006) found that Black and Hispanic Medicare beneficiaries
have lower total and out-of-pocket expenditures in comparison to their
white counterparts. Other studies indicate that African American and
Latino adults are less likely to fill their prescriptions because of the
associated expenses (Reed, 2005; Reed & Hargraves, 2003). While the
primary explanation for these disparities has focused on lack of access
to health care, some scholars have alluded to minority patients’ re-
luctance and apprehensions towards prescription medicines as reasons
for racial differences in prescription drug usage (Gaskin et al., 2006).
Various social researchers have referred to the general trend to-
wards increased prescription drug usage. Williams, Martin, and Gabe
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(2011) describe this trend as "pharmaceuticalization," which involves
“the translation or transformation of human conditions, capabilities and
capacities into opportunities for pharmaceutical intervention” (p.711).
What is often overlooked in explanations for increased prescription
drug usage is the way in which some individuals resist pharmaceuti-
calization processes. In this paper, we endeavor to fill this gap in the
literature by examining the role marginalization in the mainstream US
society, as measured by acculturation and race, contributes to differ-
ences in patients’ subjective experiences and responses to prescription
drugs. In general, racial minority groups in the US are relegated to the
margins of society compared to whites, and though they are exposed to
the same pharmaceuticalization processes and pressures, they may have
a propensity to reject these forces in favor of other alternatives. Here,
through an analysis of six focus groups of patients who had been re-
cently prescribed a prescription drug, we investigate racial variability
in how patients subjectively respond to pharmaceuticalization pres-
sures.
2. Theoretical framework
Our exploration of marginalization and prescription drug usage
draws from two main theoretical literatures: the pharmaceuticalization
of society and the social nature of medicine. Together, these two re-
search areas enable us to view health behavior as a by-product of so-
cietal changes over time while taking into consideration collective and
individual understandings of health and medicine.
2.1. The pharmaceuticalization of society
Changes in recent decades in the amount of attention directed to-
wards pharmaceutical drugs and the pharmaceutical industry (Bell &
Figert 2012), as evidenced by the growth in prescription drug sales
beginning in the 1980s (Abraham, 2010; Angell, 2004), have led to the
development of the concept of pharmaceuticalization. This concept
draws from the well-known concept of medicalization, a process in
which a non-medical condition comes to be recognized, treated, and
understood as a legitimate health issue (Barker, 2008, 2010; Conrad,
1992, 2005, 2007). Busfield (2017) argued that medicalization has
explanatory value in contemporary society because it transforms ev-
eryday understandings of human behavior, experiences, and problems,
and can have major social consequences, including closing off alter-
native solutions (Busfield, 2017).
While medicalization and biomedicalization have helped us to un-
derstand the social and technological ways in which biomedicine has
expanded into uncharted territory, they only go so far in explaining the
hold that drugs, specifically, have had in shaping treatment models.
Although interrelated, pharmaceuticalization is a separate phenomenon
from medicalization and biomedicalization since, according to
Abraham (2010): 1) treatment regimens do not always include drugs
and users do not necessarily have to purchase a medicine with a pre-
scription; 2) pharmaceuticalization can occur without an expansion of
medicalization; and 3) pharmaceuticalization can operate without or in
opposition to biomedicalization.
As the concept of pharmaceuticalization itself was introduced less
than ten years ago (Abraham, 2009), the pharmaceuticalization litera-
ture remains relatively nascent and is primarily concerned with macro-
level analyses of institutions, structures, and collective actors. Much of
this literature has focused on the pharmaceutical industry’s regulatory
practices (e.g., Abraham, 2010) the unequal distribution of drugs in
developing countries (e.g., Petryna, Lakoff, & Kleinman, 2006), gov-
ernments’ contributions to the pharmaceuticalization of society (e.g.,
Elbe, Roemer-Mahler, & Long, 2015), the industry’s investments in re-
search and development (e.g., Fisher, Cottingham, & Kalbaugh, 2015),
global drug market innovations (e.g., Sariola, Ravindran, Kumar, &
Jeffery, 2015), and the role of law and legal processes in pharmaceu-
tical flows (e.g., Cloatre & Pickersgill, 2014). Less
pharmaceuticalization research has emphasized micro-level aspects of
pharmaceuticalization by exploring patient expectations, meanings,
and experiences with pharmaceutical drugs (Brown, de Graaf, Hillen,
Smets, & van Laarhoven, 2015) and by assessing the norms and un-
derstandings of how pharmaceutical drugs become an embedded aspect
of everyday life (Thomas, 2016).
With a few minor exceptions (see Pollock & Jones, 2015), the ex-
isting literature on pharmaceuticalization has not yet addressed racial
variations in patients’ relationships to prescription drugs. Therefore, we
draw from a second body of literature regarding the social nature of
medicine, since this research focuses on micro-level processes and treats
patients as active agents in their own health.
2.2. The social nature of medicine
While the pharmaceuticalization literature focuses on macro-level
processes of pharmaceutical drug production and consumption, a body
of work draws attention to pharmaceutical drugs as cultural commod-
ities with social functions and meaning (Nichter & Vuckovic, 1994; Van
der Geest, 2006; Whyte, Van der Geest, & Hardon, 2002). For example,
Nichter and Vuckovic (1994) note that health ideologies are reproduced
through the act of taking medicine, an act that embodies subtle ideas
about the self, illness causality, and meanings of sickness (Nichter &
Vuckovic, 1994). Modern or traditional values are expressed in con-
sumption behaviors of prescription drugs, which often reflect one’s
orientation to modernity and certain lifestyles. Therefore, the use of
drug alternatives such as herbal remedies may suggest a resistance to-
wards modern western societies and biomedical models of health and
the body (Nichter & Vuckovic, 1994). Further, consumption of western
medications that offer “quick fixes” to symptoms may alienate some
individuals from their own bodies and cultural models of health
(Nichter & Vuckovic, 1994).
One of the most prominent themes explored in this literature is the
link between medicines and social change. Switching to or using a
specific type of medical system might indicate a kind of opposition to
power and authority, especially if the established medical system in a
society is aligned with the values and beliefs of the dominant group
(Nichter & Vuckovic, 1994). Van der Geest (2006) pointed to the
fluctuating symbolism associated with medicines in diverse societies or
between different groups in societies, where medicines can be used as
instruments of domination or freedom, used for harm or for benefit, and
used as material objects of possession or as mediums of assertion.
Likewise, support for traditional medicines through civic discussions
has often been used as a mechanism of struggle against colonial dom-
inance in that it has proven to be crucial in promoting cultural identity
in periods of social change (Nichter & Vuckovic, 1994). Although there
is increasing prescription drugs usage around the globe, several low-
income countries have expressed opposition to a Western approach to
medicine and have used medicine to express cultural and political
identities (Whyte et al., 2002).
Some scholars have suggested that acceptance of or resistance to-
ward pharmaceutical medicines is associated with differing identities.
For instance, Fox and Ward (2006) suggested that health identities
develop as particular expressions of physical, cultural, technological,
and emotional contexts and found that health identities varied from
“expert patient” to “resisting consumer.” Therefore, health identities
must be recognized in conjunction with the bodily self and its asso-
ciated physical, psychological, and social contexts. In addition, Collin
(2016) highlighted the centrality of pharmaceuticals in the lives of in-
dividuals in Western societies and theorized its role in the development
of collective identities. For some individuals, taking medicines enables
the control of one’s body and health; however, for others, this control
over body and health is achieved by not taking any medicines (Collin
2016).
Few scholars have explored how individuals’ racialized or margin-
alized identities influence their consumption of medicines. Several
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studies have empirically examined differences in prescription drug use
by race (Chen et al., 2005; Han & Liu, 2005; Kuno & Rothbard, 2002;
Piette, Heisler, Harand, & Juip, 2010; Schore, Brown, & Lavin, 2003). In
general, the results from these studies have indicated that whites use
prescription drugs more frequently compared to racial minorities. In
addition, some studies have shown that minority groups in comparison
to whites are more likely to hold negative beliefs regarding prescription
drugs (Iosifescu, Halm, McGinn, Siu, & Federman, 2008; Lu et al., 2008)
and are also more likely to be concerned about the side effects and over-
reliance on medications (Copeland, Zeber, Valenstein, & Blow, 2003;
Huang et al., 2009). However, even though a few of these studies have
alluded to the importance of considering cultural factors in explaining
these differences (Cooper et al., 2003; Han & Liu, 2005; Iosifescu et al.,
2008), the major emphasis in most studies has been limited to access-
related factors. To explore racial marginalization as it relates to phar-
maceuticalization, we examine how patients express themselves
through their subjective experiences with pharmaceutical drug usage.
3. Methods
3.1. Study design
This paper stems from an exploratory study investigating racial
differences in patients’ experiences with direct-to-consumer advertising
(DTCA). We organized the participants into three types of focus groups
based on racial majority-minority status and language preference: 1)
non-Hispanic, English-speaking whites; 2) minority English-speakers; 3)
minority Spanish-speakers. We conducted two focus groups of each
type for a total of six focus groups. To assess marginality, we used two
variables: race and acculturation. We operationalized acculturation
using language, as language is a commonly accepted measure of ac-
culturation in research (Lara, Gamboa, Kahramanian, Morales, & Hayes
Bautista, 2005; Marín, 1992).
3.2. Operationalization of race
We allowed for participants to self-identify their race and ethnicity.
We align with researchers (Rockquemore & Brunsma, 2002) who have
argued that racial identity is malleable and that it has structurally and
culturally defined parameters. In our study, we highlight the centrality
of race as a system of classification in US society. We acknowledge that
race is a social construction and that racial categories are in a state of
constant flux as racial ideologies in society undergo restructuring owing
to political conflicts and social changes (Omi & Winant, 2003). We
recognize that it is important to emphasize the ideology and the social
circumstances in which racial divisions are created (Doane and Bonilla-
Silva, 2013). Researchers have noted a gap between self-identification
of race and public categorizations of race (Brunsma, 2006;
Rockquemore & Brunsma, 2002), where, for some, there is a mismatch
between public categories and private identities (Brunsma, 2006).
Following Bonilla-Silva (2001), we focus on the persistence of white-
ness as a category of domination through which divisions are created
and maintained. Hence, in this study we identify broad differences
between whites and minorities rather than between whites and specific
racial subgroups.
3.3. Study context
We conducted our research in Miami Dade County, a location that
was exemplar to conduct research on racial differences in prescription
drug usage. Hispanic or Latinos account for an estimated 64% of the
Miami-Dade population, followed by whites at 16%, and then Black or
African Americans at 17% (US Census Bureau, 2015).
3.4. Recruitment and participants
The recruitment sites included two locations at a large, metropolitan
university. One location was the university’s main campus and the
other was the university’s teaching hospital located approximately nine
miles from the main campus. Most of the participants were recruited
from the teaching hospital, a prime location to gather participants for a
health-related study. This study utilized multiple recruitment methods
including posting flyers at established recruitment sites, physically
passing out flyers to potential participants at these sites, and including
announcements in the campus online newspaper. We posted English
and Spanish versions of the flyers. Members of the research team
screened all interested respondents over the phone in the respondents’
preferred language to determine their eligibility. During screening, a
team member informed potential participants of the project’s objectives
and the focus group process. A member of the research team contacted
eligible, interested individuals again over the phone to complete a so-
ciodemographic survey to gather information on their race, age,
gender, income, and education, to discuss the details of the informed
consent form, and to schedule each participant’s focus group meeting.
Because the study was concerned with how DTCA influences pa-
tients’ treatment perceptions and behaviors, we utilized a purposive
sample of individuals who had recently (within the past year) seen a
drug advertisement and had been prescribed a drug in the past year. All
participants were English and/or Spanish speakers and at least 18 years
of age. The sample size of 24 study participants, with an average of four
participants in each focus group, was intentionally small to gain an in-
depth understanding of a relatively unexplored topic. Of the 24 parti-
cipants, 15 were women and nine were men, with the youngest aged 20
and the oldest 68 years of age. Sixteen participants had at least some
college education and two had a high school education or less (six re-
fused to respond to the question). Nine participants had an annual in-
come of less than $20,000, four participants between $20,000-$49,999,
two participants between $50,000-$99,999, and one participant had an
income over $100,000 (eight participants refused to answer the ques-
tion). There were no apparent differences in income or education by
focus group. Thirteen participants were Hispanic, six were non-
Hispanic White, and five were African American.
3.5. Data collection
We collected our data between June 2014 and August 2015. Each
focus group was moderated by one author and included one to two
researchers who served as notetakers. The focus group moderator used
an interview guide that contained open-ended questions to elicit group
participation and discussion on key topic areas, including various facets
of DTCA and patient-doctor interactions. The questions were designed
to facilitate a focused discussion and to optimize consistency across
focus groups on the topic areas. During the interview, each notetaker
engaged in memoing (Creswell and Creswell, 2017; Hycner, 1985),
which contained the notetakers’ theoretical and/or methodological re-
flections on and impressions of the discussion. Immediately after the
discussion, the moderator and notetaker(s) met to discuss these notes
and their general impressions of the focus group. The focus groups were
audio recorded and lasted between 45 to 120min.
3.6. Data analysis
We aimed for an abductive approach to understand the views of the
participants in our sample (Timmermans & Tavory, 2012). Abduction is
a non-linear analytical approach in which researchers move back and
forth between theory and empirical data to establish a deeper under-
standing of a phenomenon of interest. Abduction is often marked by the
discovery of unexpected findings in the data that are pursued by ana-
lyzing variations across a study with an existing theory in mind. While
our larger DTCA project was not initiated with a sole focus on
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prescription drug experiences, we found clear racial differences in the
discussions regarding participants’ perceptions of and experiences with
prescription drugs. Thus, we turned an unanticipated observation into
an exploration of marginality and prescription drug usage. This paper
reports on the prescription drug-related findings of the focus groups.
After the data collection, transcription, and translation of focus
group interviews, we reviewed the transcripts and memos to identify
recurring themes in the discussions to create a coding scheme. Once the
coding scheme was finalized, we followed a procedure outlined by
Campbell, Quincy, Osserman, and Pedersen (2013) wherein units of
meaning rather than units of analysis are used as the basis for analysis.
This procedure involves one member of the research team who is an
expert in the project's focal area of study demarcating appropriate
blocks of text in a document for a code or codes. This demarcation was
based on the code definitions created by the research team. We used
units of meaning because standardized units of analysis (such as a
paragraph or sentence) run the risk of decontextualizing the intended
meaning of a respondent (Garrison, Cleveland-Innes, Koole, &
Kappelman, 2006), which we wanted to preserve.
The coding scheme was developed prior to the demarcation of the
units of meaning because the exact size of the units did not determine
the identification of themes. In our project, one author was an expert in
DTCA and consumer health behavior and, thus, identified the mean-
ingful units of analysis. Then, two other team members, who were blind
to the other author’s assigned codes, independently assigned their own
codes to each unit of meaning. To establish reliability, we followed
Syed and Nelson (2015), who contended that establishing reliability
must be approached as an evolving process rather than as a product.
Therefore, all parties consistently finalized the reliability of the codes
and the definitions of the codes. While initially there was a minor
amount of variability in the three authors’ codes, most of this was due
to the discriminant capability problem inherent in much qualitative
research, which refers to the difficulty for coders to keep track of
multiple codes at one time (Fahy, 2001; Kurasaki, 2000). These three
team members resolved all discrepancies in the codes through discus-
sion to reach a consensus.
4. Findings
4.1. “In the United States, everything is medicine”: Minorities’ resistance to
prescription drugs
Our results show that minority participants engaged in a process of
resistance towards the pharmaceuticalization of their bodies.
Minorities’ greater skepticism of the value of prescription drugs com-
pared to whites revealed itself in two ways. First, a major concern of
minorities about prescription drugs centered on side effects. Many
minorities indicated they were afraid to take medications because of the
possibility that they may experience side effects, many of which they
perceived to be severe in nature:
The side effects can be deadlier than the problem you have already
(Andre, English-speaking minority).
Absolutely. Mmhm (Cecilia, English-speaking minority).
You have to think twice about it (Andre, English-speaking minority).
This fear was at times actualized and at other times speculative.
Many minority participants reported that they halted drug use because
of the unbearable side effects, as indicated by the following quote:
I stop[ped] taking the medication because it made my vision blurry.
I could not read. When I saw the doctor and I asked him to change
the medication, to give me another, what he did was lower the
milligrams to see if that would help. But I was already afraid of
taking the medication, and I didn’t take it. (Mateo, Spanish-speaking
minority).
Minorities who had no experience with negative side effects were
nonetheless concerned about the potential to incur side effects and
indicated uncertainty as to how to weigh the benefits against the risks
of drug use. The same participant, Mateo, complained that he was
confused “that sometimes the side effects are worse than the ones you
are trying to alleviate.”While whites were also concerned with negative
side effects, they were less fearful of them compared to minorities.
Susan, a white participant, did not express fear around side effects but
instead viewed them as the costs associated with drug use:
You have to evaluate how serious is your condition. How much do
you need a product of that power or whatever? And if you decide to
take it and you get the side effects, then you always have the option
to stop (Susan, English-speaking, non-Hispanic white).
Whites, but not minorities, mentioned that effective communication
with doctors about side effects enabled them to come to a treatment
decision. Jeff, a white participant, discussed how his close relationship
with his doctor was instrumental in getting prescribed a drug that
minimized side effects:
Well, really, before trying the drug, we tried different drugs to see
how it affects me. Some of them actually caused more allergies to
me. Then he would actually ask me. Usually, it was him that was
asking me. I’d call him, and he would ask me, ‘so what are the side
effects of this drug that we’ve tried?’ I guess he was just asking me,
‘are you getting any other side effects? Should we try anything else?’
(Jeff, English-speaking, non-Hispanic white).
Unlike Mateo, Jeff had a doctor who was motivated to elicit feed-
back about a drug’s side effects. In general, minorities reported that
their doctors did not initiate conversations about side effects and that
they felt that they needed to educate themselves. However, the min-
ority participants believed that doctors should better manage patient
uncertainty about a drug’s side effects, as doctors are experts and
should initiate conversations with patients about whether the benefits
of a drug outweigh the risks, as mentioned by Belen:
Well, one can be influenced by the side effects, telling oneself, ‘Well,
with so much [negative] things, better I not take the medication.’
Yet, it is the obligation of the pharmacists—that also includes doc-
tors—of the side effects. Even if it is only one of the side effects that
is affecting you. (Belen, Spanish-speaking minority).
Minorities were also critical of prescription drugs for cultural rea-
sons. Their resistance to pharmaceuticalization involved a critical
questioning of mainstream American health lifestyles and the hold that
American culture’s reliance on drugs has over their experiences and
bodies. One Spanish-speaker, Mateo, claimed, “Here nobody walks. All
of that makes you sick, and they make you take medicine.” Minorities
referenced the health lifestyles associated with their cultures in their
criticisms of Americans’ problematic relationship with pharmaceuticals.
Consider this exchange among two Spanish-speaking respondents:
In the United States, everything is medicine. They send you a
medicine for your head that affects your liver, and this affects your
sight. My friend had a stroke and is now taking eight medicines.
(Mateo, Spanish-speaking minority)
In our countries, there are natural herbs, and we eat healthy.
(Alejandro, Spanish-speaking minority).
At times, whites were also critical of Americans’ overreliance on
drugs. However, they were not as concerned as minorities with the
problems associated with overprescribing, and they did not delve into
in-depth discussions of the other possible options that could be used to
thwart the need for prescription drugs. Minorities’ experiences with and
awareness of non-pharmaceutical options stemming from their culture
serve as the basis for their criticisms of prescription drugs.
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4.2. Prescription drugs versus (cultural) alternatives
Minorities’, but not whites’, discussions about prescription drugs
indicated that their culture influences their health decisions regarding
pharmaceuticals. When deciding to take a prescription drug, minorities
do not simply weigh the potential risks with the potential payoffs.
Instead, they evaluate prescription drugs vis-à-vis other remedies that
have a long history in their culture. While their evaluations are based in
part on practical assessments of the value a drug has for health,
minorities also indicate that they are tied to certain health remedies
because these remedies reflect their culture. For example, Belinda, a
Spanish-speaking participant, reported that she believed that prescrip-
tion drug alternatives are superior to pharmaceuticals as a preventative
and treatment option: “I always believe that there are better options. I
think it (the body) must heal from the inside out; a good diet is needed,
including papaya, and cherries are good anti-inflammatory sources.”
Another Spanish-speaker, Santiago, discussed how he is “skeptical and
reluctant to take medication” and only takes prescription drugs after
investigating the side effects. The following exchange among partici-
pants in a Spanish-speaking focus group also exhibits this bias against
prescription drug use:
Well, I’ll tell you something. I don’t like chemical medicines. I take
them because of my high blood pressure. I like natural things, be-
cause the truth is that garlic is more appealing to me. The truth is
that garlic is the best remedy for high blood pressure. (Jose,
Spanish-speaking minority)
… [I consumed] eggplant, also. (Valentina, Spanish-speaking min-
ority).
Beyond achieving wellness, health choices serve as a way for
minorities to engage with traditional cultural practices that differ from
those of the mainstream dominant culture. In the current study,
minorities evaluated prescription drugs by comparing them to non-
biomedical health practices common in their cultures. Our findings are
in line with research that emphasizes the role of cultural factors in
shaping approaches to health, such as studies finding that patients
choose their health care providers and treatments based on their
compatibility with their own culture’s values and norms (Cooper &
Powe, 2004; Helman, 2007; LaVeist & Nuru-Jeter, 2002; LaVeist, Nuru-
Jeter, & Jones, 2003; Saha, Komaromy, Koepsell, & Bindman, 1999;
Street, O’Malley, Cooper, & Haidet, 2008). Specifically, our findings
reveal that cultural influences affect an individual’s perception and
evaluation of pharmaceutical treatments. The following quote from an
English-speaking minority shows that, for her, familiarity with her
culture’s health remedies gives her a broader perspective on the pos-
sible ways to achieve wellness that do not necessarily involve pre-
scription drugs:
Coming from a Spanish culture—believe it or not, because my par-
ents are Cuban—they do the teas and things that worked for them
for many, many years. (Sofia, English-speaking minority).
Among white participants, prescription drug alternatives were re-
ferenced in a vague, unspecified way. For example, one white partici-
pant, Joan, noted, “…obviously there are other ways that you can deal
with whatever it is that you might have that isn’t so much on the drug
side.” Minorities, on the other hand, discussed specific alternative
therapeutic treatments for dealing with health problems. These alter-
natives included numerous lifestyle changes, such as eating more fruits
and vegetables, exercising, using herbs, and adopting a more spiritual
outlook on life. The following two participants believed that therapy is
relatively absent in the US and that it can be a useful tool for healing as
well as for health maintenance.
Here [in the US], what is lacking is therapy. I believe therapy is
important for healing. (Jose, Spanish-speaking minority)
Therapy helps you along with the medicines. (Alejandro, Spanish-
speaking minority).
While CAM definitions vary, we adhere to the definition provided
by the National Center for Complementary and Integrative Health,
which regards CAM as “practices and products of non-mainstream
origin.” Overall, our findings indicate that receptivity to CAM is based
on levels of acculturation and race. Spanish-speaking minorities refer-
enced CAM slightly more than English-speaking minorities, while
whites did not mention CAM at all. The Spanish-speaking participants
had more in-depth conversations pertaining to CAM compared to the
English-speaking minorities. These participants reported frequent use of
CAM for both preventative and treatment purposes.
More acculturated minorities discussed using CAM to combat a
variety of health concerns, including the common cold, aches and pain,
elevated blood pressure and inflammation. In one focus group, the
participants had a lengthy discussion about the best remedies for high
blood pressure:
In my case, I would take garlic, onion…. (Chuiqui, Spanish-speaking
minority)
Eggplant also. (Valentina, Spanish-speaking minority)
The truth is that for high blood pressure, garlic is the better remedy.
(Belen, Spanish-speaking minority).
Although minorities preferred to not rely heavily on prescription
drugs, they recognized the limits of CAM and that drugs were necessary
for some conditions. One English-speaking minority reported an ex-
perience where a natural remedy did not work for him:
I was trying to do it the natural way and take garlic pills because I
thought it would be better than the drug and now I’m back on the
medication because my blood pressure was so high. And it scared
me (Franco, English-speaking minority).
An acceptance of prescription drugs translated into minorities
blending aspects of their culture with a biomedical treatment approach
to devise health approaches concordant with their own identities, cul-
tures, and lifestyles. Because minorities’ spectrum of health-related
choices is broader and includes non-biomedical solutions, they have a
greater number of opportunities to practice choice. Among minorities,
culturally specific remedies were more likely to be connected to em-
powerment and one’s personal responsibility concerning health. One
Spanish-speaking minority respondent indicated the following:
It is your health, your body, your everything. Why do you have to
come and leave everything to the doctor? You have to be an in-
formed patient…inform yourself about the medication you are
taking as well as other alternatives. (Santiago, Spanish-speaking
minority).
4.3. Doctors, choice, and the importance of the “informed patient”
Overall, minorities—particularly Spanish-speakers—who praised
prescription drug alternatives also had negative evaluations of health
professionals who were not open to these alternatives. Instead, these
participants expressed that health professionals, including their own
doctors, did not fully comprehend the scope and the importance of the
use of non-pharmacological health solutions. In general, minorities’
critiques of doctors were based on their cultural expectations for the
types of remedies that doctors should promote to patients. In the fol-
lowing quote, a participant expresses frustration over doctors’ lack of
awareness of prescription drug substitutes.
Doctors do not have any idea of alternative medicines. They make
you believe there is no cure for chronic diseases. There are many
people who have managed to survive by alternative means. (Camila,
Spanish-speaking minority).
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Minorities were more likely than whites to express that most doctors
do not allow for alternative remedies in their treatment regimens.
Spanish-speaking participants also indicated that the problem of doc-
tors’ unawareness of prescription drug alternatives could be corrected
through education, and that patients play an instrumental role in get-
ting doctors to understand the value of alternative remedies. Camila, a
Spanish-speaking minority, noted, “I also think it is important for us to
educate the doctor about alternative medications. We must educate the
doctor.”
Other doctors, however, are aware of prescription drug alternatives,
and many Spanish-speaking minorities revealed that they seek out
doctors who align with their own views of prescription drug alter-
natives. Some participants mentioned that they prefer minority doctors
because, from their perspective, they are more receptive to prescription
drug alternatives. The following quote from a Spanish-speaker suggests
that he gravitates towards doctors who are open to his preference of
prescription drug alternatives:
The doctor already knows my tendency [to use] alternative medi-
cines. I try by all means [to] go that route and I tell the doctor. The
doctor already knows I do not like to take this (traditional medi-
cine). (Santiago, Spanish-speaking minority).
Unlike Spanish-speaking minorities, English-speaking minorities
who initiated discussions about prescription drug alternatives tended
not to evaluate doctors negatively based on their views of prescription
drug alternatives. In one exchange in an English-speaking minority
focus group, a participant explained that sometimes minorities err in
attempting to self-treat:
Like, my doctor can’t be a secretary so why am I trying to be a
doctor. Like sometimes we have… we say, ‘Oh, child, take a root tea
or take this or that…honey, and you be feeling better.’ Instead of
listening to what the doctor says so you know my stomach’s been
hurting for three weeks but Ima keep on takin’ this Pepto Bismo, but
really I got a big old ulcer. (Sofia, English-speaking minority).
Because the focus groups were designed to explore patients’ views of
and experiences with DTCA, all focus groups naturally involved dis-
cussions of the consumeristic culture in the US and the role con-
sumerism played in their personal health choices. All participants, re-
gardless of race, valued consumer choice and input in treatment
decisions. Many participants reported searching for more information
about potential treatments in order to have an informed conversation
with their doctor:
I do a lot of research. I do my due diligence. Whatever might be
going on, or whatever I’m experiencing. I want to know, you know?
So that I can have an intelligent, informative conversation with the
doctor (Susan, English-speaking, non-Hispanic white).
In general, while all participants were critical of pharmaceutical
companies’ motives behind advertising to patients, participants none-
theless supported DTCA, the primary reason being that participants
valued patients’ rights to know important information about pharma-
ceuticals. Most participants indicated that a good consumer is an in-
formed consumer, and good health is contingent on the active in-
volvement of the patient. Further, some participants argued that patient
involvement aids doctors in treating patients, as suggested by an
English-speaking minority:
You have to be informed, and you have to be aware of how you feel.
Sometimes you have to tell the doctor how it [treatment] is making
you feel because they don’t know. You have to be aware of your
body. (David, English-speaking minority).
That minorities shared sentiments that were similar to those of
whites about the importance of being informed is significant given that
existing research (Levinson, Kao, Kuby, & Thisted, 2005;
Ratanawongsa, Zikmund-Fisher, Couper, Van Hoewyk, & Powe, 2010)
has indicated that minorities are less involved in their treatment deci-
sions. Many minorities indicated they are not satisfied with how doctors
communicate with them. This could in fact discourage a patient’s in-
volvement in health decisions, as the following Spanish-speaking min-
ority mentioned:
I believe that because doctors are educated, many times we do not
inform ourselves [about the medication]. Other times, we allow
others to speak for us. (Alejandro, Spanish-speaking minority).
While whites also had criticisms of doctors, it is possible that their
relatively similar cultural capital to doctors allows them to better resist
doctors’ orders in the face of disagreement or to have better quality
conversations about the risks and benefits of drugs. Research has shown
that racial concordance between patients and doctors results in better
communication and higher levels of patient satisfaction (LaVeist &
Carroll, 2002; LaVeist & Nuru-Jeter, 2002). Minority patients’ greater
use of and insistence on alternative remedies may negatively impact the
patient-doctor relationship with white doctors, who may prefer phar-
maceutical treatments over other options.
5. Discussion
The minorities in this study expressed resistance towards pharma-
ceuticalization, which is reflected in a fear of the uncertainties asso-
ciated with the negative side effects of drug use. Minorities’ resistance
to pharmaceuticals translated into an openness to alternative solutions,
including the use of CAM and the adoption of healthy lifestyle changes,
by less acculturated minorities. Minorities’ resistance to prescription
drugs and their eagerness to explore other remedies affected their views
of doctors and their behavior in the doctor-patient relationship. While
all participants valued choice in health decision-making, less accultu-
rated minorities had greater opportunities to exercise choice due to
their openness to health alternatives not represented in mainstream
medicine. Minorities’ receptivity to prescription drug alternatives led
them to regard doctors who prioritize prescription drugs in treatment
regimens unfavorably.
The findings presented here suggest that minorities’ marginal posi-
tion in US society leads them to navigate the health environment dif-
ferently than whites. The way patients navigate the Western traditional
biomedical health model reflects processes of medical colonialism (see
Edwards, 2010; Huntington, 1966; Kenwood & Lougheed, 1999;
Nichter & Vuckovic, 1994; Sharma, 2006), whereby medical authorities
attempt to colonialize all aspects of human life, including health, in the
pursuit of profit and power. This leaves marginalized groups unable or
unwilling to fully acculturate to modern Western biomedical practices
of health because of their positionality (Nichter & Vuckovic, 1994). Our
findings suggest that racial minorities’ understandings of appropriate
health behaviors and treatments do not reflect the mainstream biome-
dical logic in the US, which emphasizes, promotes, and encourages the
consumption of pharmaceutical drugs.
5.1. Theoretical implications of research
Our findings lead to at least two broader theoretical implications.
First, these findings represent a need to refine the concept of pharma-
ceuticalization to acknowledge the great deal of variability toward
pharmaceuticalization processes in Western contexts along racial,
ethnic, and socioeconomic lines. This requires researchers to move past
a focus on macro-level, institutional drivers of pharmaceuticalization to
examine how meso- and micro-level processes interact with societal-
level pharmaceuticalization trends. The social nature of medicine lit-
erature reveals how individuals draw on their racial and ethnic cultures
to construct health identities that may resist the dominant biomedical
model. Our research supports conclusions from this literature—namely
that a rational-based perspective on drug use offers only a limited
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explanation as to why people use prescription drugs. While we do find
that minorities weighed the costs and benefits of prescription drug use
versus prescription drug alternatives in a rationalized way, minorities
also expressed a preference for non-pharmaceutical options for identity
reasons. Minority participants’ disdain for traits associated with the
mainstream health lifestyle in the US shows that minorities are un-
supportive of the use of pharmaceuticals as “quick fixes” for health
problems. In deciding to limit the use of prescription drugs, minorities
may be using “medications as vehicles of ideology” (Nichter &
Vuckovic, 1994) to express a medical self that resists pressures of
pharmaceuticalization and other forms of medical colonialism.
Second, these findings highlight the need for researchers to explore
acculturation as a potential factor that predicts minorities’ health be-
haviors. Our finding that less acculturated minorities were more likely
to use CAM supports the fact that minority groups have stronger ties to
the health solutions of their racial and/or ethnic backgrounds. The less
acculturated Spanish-speaking minorities drew from their own cultural
frames to manage health issues. On the other hand, the more accultu-
rated English-speaking minorities were less likely to draw on alter-
native health care options. Minorities who are less acculturated may
experience greater tension and conflicts with the health care system,
leading to their aversion to prescription drugs and greater receptivity to
alternatives. Researchers seeking to understand and explain minorities’
health behavior should consider acculturation in their investigations of
minorities’ relationship to the biomedical model.
Although current findings suggest differences in participants’ navi-
gation of the US healthcare system based on race and acculturation,
future research should take into account additional indicators such as
education and other measures of socioeconomic status in order to parse
out more nuanced differences. Such avenues, as suggested by other
analyses of racial health disparities (Grollman, 2012), could provide
additional insight into racial and ethnic minorities’ acculturation status
on the effects of health behaviors in the US. Further research should
also investigate variations among racial and ethnic subgroups in their
relationship to the biomedical model, prescription drug usage, and
CAM.
5.2. Public health implications of research
This research has several implications for policy and public health
research. The results here may partly—but not entirely—account for
unexplained variations in research on the causes of health disparities in
prescription drug usage. Public health research conceives of minorities’
lower rates of prescription drug usage compared to whites as a problem
of lack of access. While lack of access is undoubtedly an important
factor, our findings support Gaskin and colleagues’ (2006) speculation
that racial disparities may also be due to patients’ skepticism about
medicine as an effective treatment option. Our findings also support
research that has shown that racial minorities hold more negative be-
liefs of prescription drugs (Iosifescu et al., 2008; Lu et al., 2008) com-
pared to whites as well as studies (Copeland et al., 2003; Huang et al.,
2009) that have found that minorities are more likely to be concerned
about the side effects and overreliance on medications. We find that
minorities’ skepticism does not express itself in a staunch stance against
prescription drugs but rather manifests in a desire to pursue alternatives
to avoid the negatives associated with drugs.
Findings from the current study may also inform research and po-
licies directed at improving the quality of minorities’ relationship with
doctors. Our findings suggest that a primary driver of miscommunica-
tion between the doctor and the Spanish-speaking minority patient is a
disagreement, spoken or unspoken, regarding views towards pharma-
cological health solutions and alternative remedies. Since doctors are
drivers of pharmaceuticalization, minorities may feel out of place when
they vocalize their preferences for alternatives to doctors. These find-
ings support and contribute to research on the relationship between
culture, language, and the doctor-patient relationship. For example,
Street et al. (2008) found that the physician-patient relationship is
strengthened when patients see themselves as similar to their physi-
cians in terms of personal beliefs, values, and communication. Differ-
ences between doctors and minority-patients in their views of phar-
maceutical drugs and alternative remedies have important implications
on the relationship between doctors and minorities.
Lastly, public health researchers and policymakers regard low rates
of drug compliance as a serious public health problem. These discus-
sions present a view of doctors as paternal, authoritarian, and in control
and depict the “good patient” as passive, obedient, and willing. Social
scientists (Holm, 1993; Stimson, 1974; Trostle, 1988) have criticized a
compliance perspective, claiming that it paints non-compliant patients
as troublemakers and does not allow room for the expression of pa-
tients’ treatment preferences. In a context dominated by a logic where
medications are the only legitimate way to treat disease, patient com-
pliance is centered around drug use. However, some physicians (e.g.,
Weil, 2017) are starting to shed light on the negative consequences of
Americans’ overreliance on medications, citing addiction and perma-
nent physical side effects as dangerous implications of long-term drug
use. If these critical physicians are correct about the dangers of phar-
maceuticalization, minorities’ disdain for drugs may accrue health
benefits and may be contributing to the healthy immigrant effect (the
epidemiological finding that despite their relatively lower socio-
economic status, immigrants’ health outcomes are comparable to non-
Hispanic whites). Less acculturated immigrants may be experiencing
health benefits because they are not relying heavily on prescription
drugs and are protected from the risks associated with pharmaceuticals.
Non-compliance scholars should be mindful of the ways minorities’
resistance to the biomedical model might advantage their health.
5.3. Limitations of study
One limitation of this study is that it was unable to investigate in-
depth the health models of specific racial and ethnic subgroups and
how they may differ from mainstream health approaches in the US.
Some cultures may be more receptive to prescription drugs and other
aspects of the American health lifestyle than others. Qualitative re-
search among specific racial and ethnic subgroups can shed light on the
substance of minority patients’ health logics and how their culturally-
specific health approaches affect their navigation of the US health
system. Another limitation of this study is that we were unable to in-
vestigate variations by education and income, primarily because many
of our participants did not disclose their socioeconomic status.
Socioeconomic status affects the degree to which individuals feel
marginalized in mainstream society and affects patients’ relationship to
health care structures. Research should explore how race, ethnicity, and
socioeconomic status interact to affect patients’ responses to pharma-
ceuticalization. Finally, our research location was unique, and our re-
sults may not travel to other contexts. Racial minorities are the over-
whelming majority in Miami Dade County, which may affect their level
of involvement in the clinical encounter since they are not as margin-
alized within this geographical context. Limitations notwithstanding,
the current study contributes to a broader understanding of how whites
and minorities differ in their views of prescription drugs as acceptable
health care treatments.
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